Immunotherapy for Parkinson's disease.
Neurobiol Dis
; 137: 104760, 2020 04.
Article
em En
| MEDLINE
| ID: mdl-31978602
ABSTRACT
With the increasing prevalence of Parkinson's disease (PD), there is an immediate need to interdict disease signs and symptoms. In recent years this need was met through therapeutic approaches focused on regenerative stem cell replacement and alpha-synuclein clearance. However, neither have shown long-term clinical benefit. A novel therapeutic approach designed to affect disease is focused on transforming the brain's immune microenvironment. As disordered innate and adaptive immune functions are primary components of neurodegenerative disease pathogenesis, this has emerged as a clear opportunity for therapeutic development. Interventions that immunologically restore the brain's homeostatic environment can lead to neuroprotective outcomes. These have recently been demonstrated in both laboratory and early clinical investigations. To these ends, efforts to increase the numbers and function of regulatory T cells over dominant effector cells that exacerbate systemic inflammation and neurodegeneration have emerged as a primary research focus. These therapeutics show broad promise in affecting disease outcomes beyond PD, such as for Alzheimer's disease, stroke and traumatic brain injuries, which share common neurodegenerative disease processes.
Palavras-chave
Alzheimer's disease; Effector T cells; Granulocyte-macrophage colony stimulating factor; Immune homeostasis; Immune transformation; Ischemic stroke; Neurodegeneration; Neurodegenerative disorders; Neuroinflammation; Neuroprotection; Nigrostriatal degeneration; Parkinson's disease; Regulatory T cells; Teffs; Traumatic brain injury; Tregs
Texto completo:
1
Bases de dados:
MEDLINE
Assunto principal:
Doença de Parkinson
/
Doença de Alzheimer
/
Imunoterapia
/
Inflamação
Tipo de estudo:
Risk_factors_studies
Limite:
Animals
/
Humans
Idioma:
En
Revista:
Neurobiol Dis
Assunto da revista:
NEUROLOGIA
Ano de publicação:
2020
Tipo de documento:
Article
País de afiliação:
Estados Unidos